Loading clinical trials...

A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease | Clinical Trials | Clareo Health

COMPLETEDPHASE2

A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease

A Double Blind, Placebo Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of Eighteen Months Of Treatment With PF 04494700 (TTP488) In Participants With Mild To Moderate Alzheimer's Disease

NCT00566397•Pfizer

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the efficacy and safety of PF 04494700 in participants with mild to moderate Alzheimer's disease.

Eligibility

Age

50 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Mini Mental State Exam (MMSE) score between 14-26 (inclusive) at screening.
•Participants must be receiving acetylcholinesterase inhibitors on a stable dose for at least 4 months prior to randomization

Exclusion Criteria

•Current evidence or history of neurological, psychiatric and any other illness that could contribute to non-Alzheimer's dementia.
•Known history of familial AD or any evidence for early onset AD known or possibly associated with genetic mutations.
•Evidence or history of diabetes mellitus Type 1 or Type 2.
•History or symptoms of autoimmune disorders.

Locations (62)

Pfizer Investigational Site

Phoenix, Arizona, United States

Pfizer Investigational Site

Sun City, Arizona, United States

Pfizer Investigational Site

Irvine, California, United States

Pfizer Investigational Site

Irvine, California, United States

Pfizer Investigational Site

Irvine, California, United States

Pfizer Investigational Site

Irvine, California, United States

Pfizer Investigational Site

La Jolla, California, United States

Pfizer Investigational Site

Los Angeles, California, United States

Pfizer Investigational Site

Los Angeles, California, United States

Pfizer Investigational Site

Martinez, California, United States

Key Dates

Start Date

December 1, 2007

Primary Completion Date

December 1, 2010

Completion Date

December 1, 2010

Last Updated

November 30, 2018

Enrollment

402

ACTUAL participants

Conditions

Alzheimer's Disease

Interventions

PF-04494700

DRUG

PF-04494700

DRUG

Placebo

DRUG

ACP-204 in Adults With Alzheimer's Disease Psychosis

NCT06159673

Alzheimer's Disease Psychosis

View study

RECRUITING

Lombard Cohort of Brain Health Services

NCT07457138

Subjective Cognitive Decline (SCD)Functional Cognitive Disorder+2 more

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 30, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease

Inclusion Criteria

Exclusion Criteria

ACP-204 in Adults With Alzheimer's Disease Psychosis

Lombard Cohort of Brain Health Services

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function

Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia